Extended Data Fig. 3: Predicted serum ID80 titer (PT80)-predicted prevention efficacy over time in the context of viruses circulating in each of the AMP trials for the bnAb regimen PGDM1400LS + PGT121LS + VRC07-523LS at 20 + 20 + 20 mg/kg or 40 + 40 + 40 mg/kg, delivered intravenously every 24 weeks and evaluated in study cohorts of the same sizes as the AMP trials. | Nature Medicine

Extended Data Fig. 3: Predicted serum ID80 titer (PT80)-predicted prevention efficacy over time in the context of viruses circulating in each of the AMP trials for the bnAb regimen PGDM1400LS + PGT121LS + VRC07-523LS at 20 + 20 + 20 mg/kg or 40 + 40 + 40 mg/kg, delivered intravenously every 24 weeks and evaluated in study cohorts of the same sizes as the AMP trials.

From: Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Extended Data Fig. 3: Predicted serum ID80 titer (PT80)-predicted prevention efficacy over time in the context of viruses circulating in each of the AMP trials for the bnAb regimen PGDM1400LS + PGT121LS + VRC07-523LS at 20 + 20 + 20 mg/kg or 40 + 40 + 40 mg/kg, delivered intravenously every 24 weeks and evaluated in study cohorts of the same sizes as the AMP trials.The alternative text for this image may have been generated using AI.

Solid line: median. Shaded area: 95% prediction interval. Predictions made under the scenario that PGT121LS and PGDM1400LS have 2.5-times higher half-lives as PGT121 and PGDM1400, using observed serum concentration data18,19. The viruses circulating in each trial are: (a) the m = 47 viruses acquired by n = 29 703/081 (Sub-Saharan Africa) placebo recipients; (b) the m = 70 viruses acquired by n = 35 704/085 (Americas + Switzerland) placebo recipients. The PT80 of the triple-bnAb regimen was calculated using the Bliss-Hill interaction model of the individual bnAb PT80 titers10.

Back to article page